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Abstract
Background: Knowledge of the age-specific prevalence of seroprotection and incidence of seroconversion infection is
necessary to complement clinical surveillance data and statistical models. It provides the basis for estimating the future
impact of influenza A (H1N1pdm09) and implementing appropriate prevention and response strategies.
Methods: Using a cross-sectional design, two-stage stratified sampling and paired plasma samples, we estimated the age-
specific prevalence of a protective level of H1N1pdm09 antibodies in the French adult population before and after the
2009/10 pandemic, and the proportion of those susceptible that seroconverted due to infection, from a single sample of
1,936 blood donors aged 20–70 years in mainland France in June 2010. Samples with a haemagglutination inhibition (HI)
titre $1:40 were considered seropositive, and seroconversion due to infection was defined as a 4-fold increase in titre in the
absence of H1N1pdm09 vaccination or pre-pandemic seropositivity.
Results: Out of the 1,936 donors, 1,708 were included in the analysis. Seroprevalence before the pandemic was 6.7% (95%
CI 5.0, 8.9) with no significant differences by age-group (p=0.3). Seroprevalence afterwards was 23.0% (95% CI 17.7, 29.3)
with 20–29 year olds having a higher level than older groups (p,0.001). Seroconversion due to infection was 12.2% (95% CI
6.9, 20.5). Younger age-group, vaccination against H1N1 and being seropositive before the pandemic were strongly
associated with post-pandemic seropositivity.
Conclusions: Before the 2009/2010 winter influenza season, only 6.7% of the French mainland population aged 20–70 had a
level of antibodies usually considered protective. During the first pandemic wave, 12.2% of the population seroconverted due to
infection and the seroprevalence after the wave rose to 23%, either due to prepandemic seropositivity, infection or vaccination.
This relatively low latter figure contributed to an extension of target groups for influenza vaccination for the 2010/2011 season.
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Introduction
The pandemic wave of influenza A (H1N1) 2009 occurred in
France over 16 weeks (October 2009–January 2010) [1]. Between
8–14.8 million people were estimated to have been infected in
mainland France, from clinical surveillance data adjusted for
estimated proportions of asymptomatic cases and symptomatic
cases not reporting to health services [2]. Almost 5.2 million were
vaccinated against the pandemic A(H1N1)2009 (H1N1pdm09)
virus in a national vaccination campaign launched in November
2009, resulting in an uptake of 8% [3].
Knowledge of the prevalence of immunity after a pandemic
wave is necessary in order to estimate the future burden of disease
and to plan appropriate response strategies. Information on the
prevalence of immunity prior to the pandemic and the proportion
of the population seroconverting contributes to our understanding
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can be derived by modelling using clinical surveillance data, but
the limitations of these approaches are well recognized [4]. Direct
measurement of antibodies to H1N1pdm09 through serological
methods enhances these estimates.
Several cross-sectional seroepidemiological studies in a variety
of populations before or after the pandemic wave(s) have been
published [5]. Few have been able to obtain serial samples from
the same individuals [6–8], and thus able to directly assess the
proportion of subjects seroconverting, or the impact of a protective
level of cross-reactive antibodies before the onset of the pandemic
on subsequent seroprevalence.
We report the results of a national serological study in mainland
France carried out in blood donors, thus enabling access to linked
plasma samples taken before and after the pandemic wave in a
given individual. Our first objective was to estimate the age-
specific seroprevalence of a protective level of antibodies to
H1N1pdm09 in adults before and after the 2009/10 pandemic
wave. We also estimated the percentage of seroconversion that
could be attributed to infection. Although we based our work on
the analysis of plasma, the word « seroconversion » is used
throughout the article.
Methods
Study design
We performed a cross-sectional study of blood donors aged 20–
70 years donating during two weeks in mainland France in June
2010. We excluded donors who had not donated between January
2005 and April 2009. Donors were selected among the population
of donors presenting at a blood collection site to donate their
blood, without any screening or additional selection procedure. To
ensure a random selection of these donors, we used a random
stratified two-stage sampling design. The first stage involved
unequal probability sampling of blood collection sites proportional
to regular donor activity in June 2009, stratified by 14 mainland
French blood service (Etablissement Franc ¸ais du Sang) regions and
type of blood collection site (fixed, mobile urban, mobile rural).
Mobile sites were designated urban if they were situated in urban
units of more than 20,000 habitants using the National Institute of
Statistics and Economic Studies (Insee) classification [9]. At the
second stage, donors were randomly recruited at each selected
blood collection site (two in each 10-year age group at fixed sites
and one in each group at mobile sites). We aimed to achieve a
sample size of 350 in each 10-year age-group based on a
maximum seroprevalence of 30%, an alpha error of 5% and a
precision of 5%. To allow for possible recruitment difficulties,
blood collection sites were instructed to aim for a total of 420
donors in each age-group, or 2100 donors overall.
The study complied with the participating institutions guidelines
for human research. According to French law, formal ethical
committee clearance was not required for this study as donors
provide written consent to the use of blood samples for research as
partofstandardblood donation proceduresand all data collectedfor
study purposes were anonymous. The French Commission for Data
Protection (Commission Nationale de l’Informatique et des Liberte ´s)
gave approval for the study. On presenting to donate blood, donors
were provided with a letter explaining the study, the provisions to
ensure confidentiality, and the opportunity not to participate. Those
who gave oral consent, documented by responding to our
questionnaire, were included in the study until the target sample
size for each age-group at that blood collection site was reached.
Participating donors were questioned about influenza-like symptoms
(a respiratory infection with fever and cough and myalgia or fatigue)
from October to December 2009, and vaccination against influenza
H1N1pdm09. A sample of plasma was retained from the donation and
a stored plasma sample prior to April 2009 was retrieved. Stored
plasma samples are linked to a donor using a unique identification
number. It has been mandatory in France to store plasma specimens
from every blood donation for 5 years since 1999. At each donation,
two plasma specimens (500 mL) are prepared (Cryo Bio Straw,
Cryobiosystem, L’Aigle, France) and frozen in liquid nitrogen.
Laboratory methods
Antibody titres against influenza A/California/7/2009 (H1N1)
were measured by haemagglutination inhibition assays (HI) on all
samples using standard techniques [10,11]. To avoid misreadings
of HI titers on plasma specimens, triple readings were carried out
independently. Indeed, determination of HI titers in plasma can
be difficult due to partial reactions. To overcome this problem,
chicken red blood cells were selected, and additional readings of
the HI plates were carried out after 1 hour at +4uC. If partial HI
remained observed, the plasma was retested. Unpublished data
have shown an excellent consistency of results when using chicken
RBC rather than turkey RBC, which are not always readily
available. Titres were expressed as the reciprocal of the highest
dilution of serum where haemagglutination was inhibited.
Microneutralization (MN) assays were performed on a random
selection of 30% of sample pairs for comparison.
Statistical analysis
Each donor was assigned a sampling weight based on the
inverse of inclusion probabilities at each sampling stage. This
enabled us to account for the complex sampling design so that
donors with a greater chance of being selected had less weight than
those with a smaller chance of selection. Sampling weights were
further adjusted by age and sex using data from the 2008 French
census (National Institute of Statistics and Economic Studies,
Insee) in order to provide estimates for the mainland French
population aged 20–70 (see appendix S1). Age-specific geometric
mean titres (GMT) were calculated by assigning a value of 5 for
titres lower than 10 and 1280 for titres of 1280 or higher.
Samples with an HI titre of $1:40 were considered seropositive,
this being the titre conventionally used as it was shown to be
associated with at least a 50% reduction in the risk of infection or
disease with seasonal influenza viruses [12]. Seroconversion was
defined as a 4-fold increase in HI titre between the two samples.
For analyses estimating seroconversion due to infection, pairs with
a titre of $1:40 in the pre-pandemic sample (considered not
susceptible) or with H1N1pdm09 vaccination (alternative expla-
nation for seroconversion) were excluded. Prevalence of seropos-
itivity before and after the 2009/10 pandemic and the proportion
seroconverting was estimated by demographic factors and other
exposure variables. Log-Poisson regression models with a robust
linearized variance estimator were used to estimate adjusted
prevalence ratios for seropositivity after the pandemic and
seroconversion due to infection, since odds ratios calculated from
logistic regression models are not a good approximation of the
prevalence ratio when the prevalences in the exposed and
unexposed groups are very different [13,14] (see appendix S1).
Variables were entered into the multivariable models and removed
manually by stepwise selection, retaining those significantly
associated with the outcomes at a significance level of p#0.05.
The triple interaction between age, preexisting seroprotection and
A(H1N1)2009 vaccination status was included and tested for
significance as it was anticipated that the likelihood of post
pandemic seropositivity would differ between combinations of the
various levels of those variables.
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Institut de Veille Sanitaire team with STATA 11.2 [15], using the
svy prefix to incorporate the sampling design (stratification, stages,
weights).
Results
Between June 21
st and July 2
nd 2010, 1936 donors were
recruited to the study. Compared with samples that were taken
before the seasonal influenza epidemic of winter 2007/08 (when a
seasonal H1N1 influenza virus antigenically related to A/
Brisbane/59/2007 was the predominant circulating strain),
samples taken after the start of that season were more likely to
be seropositive to the H1N1pdm09 virus than those taken before
(crude seroprevalence 6.7% vs. 2.2% p=0.01). The association
remained significant after adjustment for age group and sex (PR
3.1, 95%CI 1.2–8.5). We therefore decided to exclude from the
analysis 228 (11.8%) individuals with a pre-pandemic sampling
date prior to December 2007 (n=193) or with an unknown pre-
pandemic sampling date (n=35). Keeping the former individuals
would have lead to underestimating the pre-pandemic seroprev-
alence and hence overestimating the risk of infection. The study
design is shown in figure 1 and the characteristics of the 1708 cases
eventually included in the analysis are shown in Table 1.
Seroprevalence before the 2009/10 pandemic wave
Seroprevalence before the pandemic was 6.7% (95% CI 5.0–
8.9%) overall with no differences by age-group (p=0.3) (figure 2),
or by sex or region (data not shown). GMTs did not differ
significantly by age-group (figure 3). MN assays using the same
threshold of 1:40, gave a seroprevalence of 11.5% (95% CI 7.3–
17.7%) overall.
Seroprevalence after the 2009/10 pandemic wave
Overall seroprevalence was 23.0% (95% CI 17.7, 29.3) with the
20–29 year age-group having a higher seroprevalence than older
groups (p,0.001) (figure 2). GMT’s of post-pandemic wave samples
were significantly higher than pre-pandemic GMT’s in all age-groups
except in 60–70 year olds, with the difference becoming less marked
with increasing age (figure 3). The percentage of the population
having a titre equal or superior to a given titre increased between
baseline and post-pandemic wave particularly at lower titres. The
increase was more marked in those aged less than 45 years than those
aged 45 and above: below 45 years, the proportion of those
p r e s e n t i n gw i t hat i t r eb e l o wo re q u a lt o4 0r o s ef r o m8 . 1 %t o2 6 . 0 % ,
whereas in those aged 45 years old or more, this proportion rose from
6.6% to 16.9% (figure4).MN assays using the same thresholdof 1:40,
gave a seroprevalence of 22.8% (95% CI 17.4, 29.3%) overall.
On univariable analysis, age-group, vaccination status, seroprev-
alence before the 2009/10 pandemic wave, sex and type of site were
significantly associated with seroprevalence (p#0.20) (table 1).
Seroprevalence was not significantly different in the absence or
presence of symptoms, and there were no significant differences by
region (data not shown). On multivariable analysis, pre-pandemic
seropositivity, vaccination against H1N1pdm09, age 20–29 and type
of blood collection site were all found to be significantly associated
with being seropositive after the pandemic (table 2). A statistically
significant triple interaction was identified between pre-pandemic
seropositivity, vaccination and age group. This was used to calculate
prevalenceratiosforallcombinationsofthesethreevariables(table2).
Prevalence was significantly higher in 20–29 year olds than 30–70
year olds in the absence of both vaccination and pre-pandemic
seropositivity. Vaccination increased post-pandemic seroprevalence
in the absence of the pre-pandemic seropositivity and vice versa.
Even in the presence of the other variable, both vaccination and
Figure 1. Number of Influenza like illness (ILI) cases seen by the French Sentinel GPs Network (Re ´seau Sentinnelle, Inserm U707),
January 2005–June 2010, and cumulative number of IHA pre-pandemic samples collected for the study, France, 2005–2009.
doi:10.1371/journal.pone.0033056.g001
Seroepidemiology of Influenza H1N1 2009, France
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e33056pre-pandemic seropostivity resulted in a small increase in prevalence
in both age-groups, although thiswas not statisticallysignificant in the
20–29 age-group.
Seroconversion
The proportion of the population seroconverting overall was
16.0% (95% CI 11.2, 22.3). In those who were not seropositive
beforethepandemic,65.4%(95%CI55.0,74.5)ofthosevaccinated
seroconverted. The proportion seroconverting due to infection was
12.2% (95% CI 6.9, 20.5), with a significantly higher proportion in
those aged 20–29 compared with other age-groups (table 3). Among
those seroconverting through infection, 89.6% (95% CI 76.7,
95.8%) reported no influenza-like symptoms during the 2009/10
wave. On multivariable analysis, age 20–29 years, mobile blood
collection sites and having had symptoms were all significantly
associated with seroconversion attributable to infection.
Table 1. Prevalence of HI titre $1:40 after the pandemic by exposure variable (weighted) (n=1708).
Variable n* Prevalence (95% CI) p
Age-group 20–29 324 46.80 [29.21, 65.21] ,0.001
30–39 325 20.88 [14.34, 29.38]
40–49 363 16.29 [10.82, 23.77]
50–59 363 14.72 [10.57, 20.14]
60–70 328 16.23 [11.39, 22.59]
H1N1 vaccination status Vaccinated 183 73.05 [63.51, 80.85] ,0.001
Not-vaccinated 1520 18.13 [12.54, 25.48]
Titer $40 before pandemic wave Yes 105 90.18 [80.85, 95.23] ,0.001
No 1592 18.21 [13.04, 24.84]
Sex Male 924 26.60 [17.35,38.49] 0.19
Female 780 19.48 [15.59,24.06]
Type of site Mobile urban 455 27.08 [17.04, 40.16] 0.15
Mobile rural 660 20.41 [17.03, 24.25]
Fixed 590 15.63 [12.18, 19.82]
Influenza – like symptoms Yes 74 30.78 [19.11, 45.57] 0.39
No 1591 22.78 [17.37, 29.27]
Don’t know 30 32.24 [14.61, 56.95]
*Totals slightly different from 1708 are explained by a few subjects with missing information for that variable (i.e. 4 subjects with missing information for sex).
doi:10.1371/journal.pone.0033056.t001
Figure 2. Prevalence of a titre $1:40 before and after the pandemic by age group, France 2010. Seroprevalence before the pandemic was
6.7%(95%CI 5.0–8.9%) overall withnosignificant differences byage-group. Seroprevalence after the pandemic was 23.0% (95%CI 17.7, 29.3) overall with
the 20–29 year age-group having a higher seroprevalence than older groups. The increase in seroprevalence was more marked in younger age-groups.
doi:10.1371/journal.pone.0033056.g002
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We found seroprevalence after the 2009/10 pandemic wave to
be 23.0% overall, with higher seroprevalences in younger age-
groups. Seroprevalence was 6.7% before the pandemic with no
significant differences by age-group. We estimated the proportion
of the population having seroconverted as a result of infection to
be 12.2%, with a significantly higher proportion in the population
aged 20–29. Our results are generally consistent with those
published from other countries although comparisons between
Figure 3. Geometric mean titres before and after the pandemic by age-group, France 2010. In the five age groups, pre-pandemic GMTs
ranged from 6.3 to 8.1 with no significant differences by age group. Post-pandemic GMTs showed a significant increase from pre-pandemic results in
all age-groups except those aged 60–70, with the increase being more marked in younger groups. Post-pandemic GMTs ranged from 9.3 to 16.1.
doi:10.1371/journal.pone.0033056.g003
Figure 4. Reverse cumulative distribution curves before and after the pandemic by age group, France 2010. The percentage of the
population having a titre equal or superior to a given titre increased between pre-pandemic and post-pandemic samples particularly at lower titres.
The increase was more marked in those aged less than 45 years than those 45 and above. Pre-pandemic titres of less than 1:40 were more common in
those aged 45 or more compared with those aged less than 45.
doi:10.1371/journal.pone.0033056.g004
Seroepidemiology of Influenza H1N1 2009, France
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techniques, thresholds etc [5].
Most estimates of the proportion of the population infected have
been extrapolated from seroprevalence data obtained from
convenience samples of different subjects before and after the
pandemic [4,16,17] [18–20], one of which also incorporated
clinical surveillance and data on seroconversion intervals collected
from pandemic influenza cases in their estimates [21]. A few
studies have estimated seroconversion before and after the first
pandemic wave using the same subjects, but again different
Table 2. Factors associated with HI titre $1:40 after the pandemic wave (multivariable analysis).
Variables Adjusted PR (95% CI) p
Age group 20–29 years compared H1N1 vaccination Titre
to 30–70 years*
Not vaccinated Titre ,1:40 pre-pandemic 4.99 [2.65, 9.38] ,0.001
Vaccinated Titre ,1:40 pre-pandemic 1.33 [0.91, 1.94] 0.14
Not vaccinated Titre $1:40 pre-pandemic 1.07 [0.87, 1.32] 0.50
Vaccinated Titre $1:40 pre-pandemic 1.12 [0.85, 1.48] 0.41
H1N1 Vaccination compared Age-group Titre
to no vaccination*
20–29 Titre ,1:40 pre-pandemic 2.57 [1.53, 4.32] ,0.001
20–29 Titre $1:40 pre-pandemic 1.30 [0.94, 1.80] 0.11
30–70 Titre ,1:40 pre-pandemic 9.63 [6.49, 14.30] ,0.001
30–70 Titre $1:40 pre-pandemic 1.25 [1.02, 1.53] 0.03
HI Titer $1:40 before pandemic Age-group H1N1 Vaccination
compared to HI titer ,1:40*
20–29 Not vaccinated 2.51 [1.41, 4.47] 0.002
20–29 Vaccinated 1.27 [0.86, 1.87] 0.23
30–70 Not vaccinated 11.65 [7.61, 17.82] ,0.001
30–70 Vaccinated 1.51 [1.25, 1.82] ,0.001
Sex - Male compared to female 1.33 [0.95, 1.87] 0.10
Type of site - Mobile urban compared to fixed 1.71 [1.22, 2,38] 0.002
Type of site - Mobile rural compared to fixed 1.36 [1.09, 1.71] 0.007
ILI symptoms compared to no ILI symptoms 1.31 [0.86, 2.00] 0.21
*Prevalence ratios calculated using variables forming the statistical triple interaction identified (age group, H1N1 vaccination and pre-pandemic titre $1:40).
doi:10.1371/journal.pone.0033056.t002
Table 3. Factors associated with seroconversion in those without pre-pandemic titre $1:40 or vaccination against H1N1.
Variable n Prevalence % P Adjusted Prevalence p
(95% CI) Ratio (95% CI)
Age-group (years) 20–29 273 40.36 [19.32, 65.67] ,0.001 6.17 [3.39, 11.24] ,0.001
30–39 265 9.98 [4.51, 20.66] Ref 30–70 years
40–49 310 3.30 [1.64, 6.52]
50–59 303 4.95 [2.71, 8.89]
60–70 272 3.29 [1.75, 6.10]
Sex Male 764 15.74 [6.50, 33.45] 0.22 1.47 [0.79, 2.73] 0.22
Female 659 8.67 [5.95, 12.47] Ref
Type of site Mobile urban 385 18.03 [8.29, 34.87] 0.02 3.25 [1.72, 6.13] ,0.001
Mobile rural 542 7.30 [5.15, 10.26] 1.88 [1.03, 3.43] 0.04
Fixed 497 4.62 [2.67, 7.90] Ref
ILI symptoms Yes 61 19.99 [10.16, 35.57] 0.38 1.88 [1.00, 3.53] 0.05
No 1330 11.94 [6.32, 21.41] Ref no or don’t know
Don’t know 26 21.06 [6.25, 51.61]
doi:10.1371/journal.pone.0033056.t003
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seroconversion in 13.5% (95% CI 11.2,16.2) of participants
providing paired samples in an unvaccinated population in
Singapore using HI assays [6]. In Hong Kong, Wu et al
performed MN assays on paired sera from 324 blood donors as
part of a larger serial cross-sectional serological study, reporting
lower seroconversion rates in all age groups aged 20–60 years,
having excluded those with a pre-pandemic MN titre of ,1:10 (for
example 5.3% (95%CI 1.7, 11.9) in 20–29 year olds) [8]. In a
community-based paired serological study again using MN assays
in Hong Kong, Riley et al reported seroconversion rates of 8.9%
(95% CI 5.3, 14.7) in 20–39 year olds and 5.3% (3.5, 8.0) in 40–59
year olds [7].
Our estimate of seroconversion due to infection is likely to be an
underestimate as we excluded those with a pre-pandemic titre of
$1:40 and those vaccinated for these analyses. However, a 4-fold
increase in antibodies as a result of infection could have occurred
in those with a pre-pandemic titre of $1:40. Subsequent analysis
indicated that of the small proportion who were seropositive
before the pandemic and unvaccinated, 3.8% mounted a 4-fold
increase in titre. Moreover, we assumed that seroconversion in the
presence of vaccination was due to vaccination, although
alternative causes could be infection prior to vaccination or
infection in the context of vaccine failure. Lastly infection may
have resulted in a less than 4-fold increase in titre.
The finding that nearly 90% of those seroconverting as the
result of infection reported not having had an influenza-like illness
was surprising as the proportion of asymptomatic or mildly
symptomatic infections in seasonal influenza is usually in the range
of 40–60% [22]. Other authors have found the proportion of
H1N1pdm09 infections that were asymptomatic or pauci-
symptomatic to be 27%–82% [6,16,23] [7,24]. However, our
definition of influenza-like illness likely excluded mild presenta-
tions of disease and problems with recall as our study was carried
out six months after the pandemic cannot be excluded.
Our pre-pandemic seroprevalence results are generally consis-
tent with other studies in this age group (20–70 years)
[4,8,16,17,20,25–28]. Higher pre-pandemic seroprevalences have
been observed in older age-groups, particularly in western
countries, but almost always in age-groups beyond the age of 70
[4,27,29–31]. One French study has reported very different results
using the HI method and a threshold titre of 1:40, with pre-
pandemic seroprevalences of between 43% and 69% in those aged
25–100 years based on a convenience sample of serum stored from
hospital patients in the Marseilles region [19]. However, these
authors also report the findings of a parallel national study of
pregnant women carried out during the pandemic with an
estimated baseline seroprevalence at the start of the pandemic of
2.4% (threshold titre 1:80). The most likely explanation for these
differences seems to be different sampling strategies, source
populations and laboratory methods. In our study, pre-pandemic
seroprevalence was higher in samples taken after the start of the
winter influenza season 2007–2008, an observation we believe has
not been previously reported. Contact with the seasonal A/
Brisbane/59/2007-like viruses, which were the predominant
viruses circulating that season, may have enhanced homosubtypic
cross-reactive immunity [32].
Our post-pandemic seroprevalence results are also compatible
with most other studies, although higher post-pandemic seroprev-
alences are reported from countries and regions with better
H1N1pdm09 vaccine uptake [18,33,34]. Post-pandemic seroprev-
alence was higher in younger age-groups, the vaccinated and in
those who were seropositive before the pandemic. Seventy-one
percent of those reporting H1N1pdm09 vaccination had a level of
antibodies usually considered to be protective in June 2010,
consistent with published estimates of vaccine effectiveness [35].
Since our study was carried out six months after the vaccination
campaign, our result may underestimate vaccine associated
protection because of waning immunity [36]. However, a meta-
analysis has been recently performed by WHO including all
published and unpublished sero-studies for the 2009 influenza
pandemic virus, including ours. It has actually shown a decrease in
seroprevalence with time, in the 40 weeks interval between sera
collection and peak in influenza activity, however this decrease
was statistically non significant. Ninety percent of those who were
seropositive before the pandemic were seropositive afterwards.
Analysis of cases where the titre dropped below 1:40 revealed
changes around the threshold (most commonly from a titre of 1:40
to a titre of 1:20) probably due to variations within the assays. In
multivariable analysis, three variables (age-group, vaccination and
pre-pandemic seropositivity) were strongly associated with sero-
prevalence and all found to modify the effect of each other (table 2).
Younger age-group was only associated with seropositivity after
the 2009/10 pandemic wave in the absence of vaccination and/or
pre-pandemic seropositivity.
A significant association was also found with type of blood
collection site, with levels of seropositivity and seroconversion being
significantly higher in populations attending mobile sites compared
with fixed sites. This difference may reflect factors influencing
exposure, such as mobility or socioeconomic differences.
Our seroprevalence results are rather different from French
modelling estimates based on general population surveillance data
(adjusted for the estimated proportion of asymptomatic infections
[22,37] and healthcare seeking behaviour [38]), which found the
proportion of the population aged 19–64 years immune to
H1N1pdm09 before the 2009/10 pandemic wave to be 36%
[38]. The disparity between the model and serological estimates
raises questions regarding which estimates reflect the real levels of
protection. Models may under or overestimate prevalence as they
use a series of assumptions. But serological assays are likely to
underestimate protection as they cannot quantify cross-reactive
immunity with closely related H1N1 viruses, nor the cross-reactive
cellular responses acquired through past infections [39,40]. As
post-pandemic wave samples were collected 6 months after the
epidemic, a decline in detectable antibody titres over time, cannot
be ruled out [36]. Furthermore, the threshold of an HI titre of
$1:40 as an indicator of seroprotection can be challenged [41],
and has not been specifically validated for H1N1 2009 or in all
age-groups. MN assays detect a broader range of antibodies than
HI but there is no established correlate of protection. If the
presence of any antibody detected by MN were to be considered
protective, seroprevalence after the 2009/10 pandemic wave
would be as much as 46% (95% CI 40, 52).
Our choice of blood donors to represent the general adult
population warrants consideration. Certain groups are excluded
from blood donation, mainly pregnant women, people presenting
with some chronic illnesses, with blood borne infections or with
risk factors for their acquisition. However we believe that this
should have a very limited impact on our estimations as those
characteristics are likely to be poorly correlated with the pre-
pandemic serostatus and the risk of infection during the pandemic
wave. The fact that the vaccination coverage of our sample (8.9%)
tended to be slightly higher that the one measured in the general
population of the same age, through the national H1N1pdm09
vaccination campaign database (6%) is not in favour of a bias
toward selection of healthier subjects [3]. Similarly, we did not
formally monitor the number of donors refusing to participate, but
we do not consider selection bias to be a significant problem as it
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the outcomes studied. A further consideration is that the blood
bank provided plasma specimens, whilst the reference techniques
described by the World Health Organization for serological assays
are based on sera. No head to head comparisons between sera and
plasma HI titres have been published, but in our experience there
are no significant differences between HI titres when using plasma
as compared to sera. Considering however that HI reactions are
sometimes incomplete with plasma, which may putatively have an
impact of HI values, we selected the most appropriate red blood
cells, and added an additional reading step after 60 min at +4uC.
With this technical adaptation, the readings were consistent, and
specimens remaining difficult to read (partial HI) were retested.
Finally, an important weakness of our study linked to our choice of
study population is that we were not able to assess seroprevalence
and seroconversion in children, the population shown by others to
have been most infected by the virus, because of the population
studied. Another serological study looking at the prevalence of
antibodies to several infections including H1N1pdm09 in a
random selection of individuals age 6–29 attending private
laboratories in France is currently being analysed.
Conclusions
Our methodology has enabled us to study seroprevalence in the
French mainland population aged 20–70 years by collecting data
from the same individuals before and after the 2009/10 pandemic
wave, and to examine the effect of vaccination and pre-pandemic
seropositivity on post-pandemic wave seroprevalence. We were
also able to provide direct estimates of the proportion of the
population seroconverting as a result of infection. We found a high
proportion of pauci- or asymptomatic infections. Pre-pandemic
seroprotection was higher in samples taken after the winter 2007/
2008 influenza season suggesting that the seasonal H1N1 virus
circulating in that season may have contributed to pre-existing
seroprotection.
Our results indicate that almost 80% of the French mainland
population aged between 20–70 years did not have a protective
level of antibodies at the start of the 2010/2011 winter influenza
season. Whether this implies that this proportion of the population
was still susceptible to influenza H1N1pdm09 virus is still unclear,
given that measurement of antibody titres alone cannot fully
quantify immunity and that models suggested higher seropreva-
lences. At the time, the season’s vaccine recommendations were to
offer vaccine to traditional at-risk groups for seasonal influenza
(those aged 65 and over and those with certain chronic diseases).
In view of our estimates, and reports from the southern
hemisphere and England and Wales of high proportions of severe
influenza cases in 2010 [42], taken with the poor uptake of vaccine
by the general population during the pandemic, the decision was
made to extend the season’s vaccine recommendations to
additional risk groups particularly affected during the pandemic
(pregnant women and obese people) [43].
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